Bioventix (BVXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioventix (BVXP) has a cash flow conversion efficiency ratio of 0.402x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.44 Million ≈ $539.88 USD) by net assets (GBX11.04 Million ≈ $1.34K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bioventix (BVXP) balance sheet quality index to measure how much of total assets are equity-financed.
Bioventix - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Bioventix's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BVXP cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Bioventix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioventix ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magle Chemoswed Holding Ab
ST:MAGLE
|
-0.006x |
|
Tangiamo Touch Technology AB
ST:TANGI
|
0.021x |
|
Jubilee Platinum
LSE:JLP
|
-0.005x |
|
Audioboom Group plc
LSE:BOOM
|
0.076x |
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
0.005x |
|
River and Mercantile UK Micro Cap Investment Company Ltd
LSE:RMMC
|
-0.007x |
|
Transforma Resources Corp
V:TFM
|
-0.010x |
|
Marshall Machines Limited
NSE:MARSHALL
|
-0.164x |
Annual Cash Flow Conversion Efficiency for Bioventix (2011–2025)
The table below shows the annual cash flow conversion efficiency of Bioventix from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Bioventix.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX11.55 Million ≈ $1.41K |
GBX7.03 Million ≈ $855.57 |
0.609x | -12.44% |
| 2024-06-30 | GBX12.00 Million ≈ $1.46K |
GBX8.34 Million ≈ $1.02K |
0.695x | +6.11% |
| 2023-06-30 | GBX12.06 Million ≈ $1.47K |
GBX7.90 Million ≈ $961.62 |
0.655x | +2.42% |
| 2022-06-30 | GBX11.82 Million ≈ $1.44K |
GBX7.56 Million ≈ $920.03 |
0.640x | +18.74% |
| 2021-06-30 | GBX11.82 Million ≈ $1.44K |
GBX6.37 Million ≈ $774.79 |
0.539x | -12.67% |
| 2020-06-30 | GBX12.52 Million ≈ $1.52K |
GBX7.72 Million ≈ $939.79 |
0.617x | +13.63% |
| 2019-06-30 | GBX10.83 Million ≈ $1.32K |
GBX5.88 Million ≈ $715.12 |
0.543x | +0.94% |
| 2018-06-30 | GBX11.01 Million ≈ $1.34K |
GBX5.92 Million ≈ $720.55 |
0.538x | +37.89% |
| 2017-06-30 | GBX10.14 Million ≈ $1.23K |
GBX3.96 Million ≈ $481.44 |
0.390x | +0.93% |
| 2016-06-30 | GBX8.21 Million ≈ $998.60 |
GBX3.17 Million ≈ $385.91 |
0.386x | +18.62% |
| 2015-06-30 | GBX6.58 Million ≈ $801.10 |
GBX2.15 Million ≈ $260.99 |
0.326x | -3.36% |
| 2014-06-30 | GBX5.24 Million ≈ $637.09 |
GBX1.77 Million ≈ $214.78 |
0.337x | +5.70% |
| 2013-06-30 | GBX4.20 Million ≈ $511.61 |
GBX1.34 Million ≈ $163.17 |
0.319x | -14.04% |
| 2012-06-30 | GBX3.34 Million ≈ $406.34 |
GBX1.24 Million ≈ $150.76 |
0.371x | +29.66% |
| 2011-06-30 | GBX2.68 Million ≈ $325.76 |
GBX766.14K ≈ $93.22 |
0.286x | -- |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more